ItalyPeptide Receptor Radionuclide Therapy (PRRT) Market, by Drug Type (Lutetium(Lu-177)-based, and Yttrium (Y-90)-based), by Indication(Gastroenteropancreatic Neuroendocrine Tumor), and by Distribution Channel(Hospital Pharmacies and Retail Pharmacies), was valued at US$ 3.6 million in2019 and is expected to exhibit a CAGR of 9.2%over the forecast period(2019-2027), as highlighted in a new report published by.
Increasing drug approvals byregulatory bodies are expected to drive the Italy peptide receptor radionuclidetherapy market growth over the forecast period. For instance, in 2018, Novartisreceived U.S FDA approval for lutetium (177Lu) oxodotreotide (Lutathera) fortreatment of somatostatin receptor positive gastroenteropancreaticneuroendocrine tumors (NETs) (GEP-NETs). Furthermore, rising number of cancercases in Italy is a major factor driving growth of the peptide receptorradionuclide therapy (PRRT) market in the country. For instance, according toEuropean Union statistics related to cancer, in 2015, about 33,851 number ofdeaths were recorded due to lung cancer in Italy.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/3139
This contributed to around 8% intotal Europe region, in which the share of all deaths attributed to lung cancerwas 7.2 % among men, more than double the share (3.4%) recorded for women inEurope region.
Moreover, according to the WHO,in 2018, a total number of 40,9,808 cancer cases were recorded in Italy, whichincluded prostate cancer, lung cancer, bladder cancer, colorectal cancer,breast cancer, and other type of cancers.
Browse 9 Market Data Tables and12 Figures spread through 64 Pages and in-depth TOC on 'Italy Peptide ReceptorRadionuclide Therapy (PRRT) Market, by Drug Type (Lutetium (Lu-177)-based, andYttrium (Y-90)-based), by Indication (Gastroenteropancreatic NeuroendocrineTumor), and by Distribution Channel (Hospital Pharmacies and Retail Pharmacies)– Italy Forecast to 2027'
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/italy-peptide-receptor-radionuclide-therapy-market-3139
Key Takeaways of the ItalyPeptide Receptor Radionuclide Therapy (PRRT) Market:
The Italy Peptide ReceptorRadionuclide Therapy (PRRT) Market is expected to exhibit a CAGR of 9.2% overthe forecast period (2019–2027) owing to increasing regulatory approvals andincidence of cancer
Among drug type, the Lutetium(Lu-177)-based segment is expected to account for a major revenue share by2027, owing to increasing strategic acquisitions by key players for expandingtheir drug portfolio. For instance, in 2017, Novartis acquired AdvancedAccelerator Applications. With this acquisition, Novartis has expanded itsproduct offering in the neuroendocrine business, through which the companyoffers the Lutetium (Lu-177)-based drug.
Major player operating in theItaly Peptide Receptor Radionuclide Therapy (PRRT) Market is NovartisInternational AG.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/3139
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
